Clinical analysis of adefovir dipivoxil for different genotype of HBV

WU Xin-yuan, LI Zhi-liang, ZHOU Ling-li

(Department of Infectious Diseases, Tongcheng People's Hospital, Hubei 437 400, China)

[Foundation Project]: This Work is Financially Supported by Special Foundation for Clinical Studies from Committee of Medical Journal of Chinese Universities (112210186)

[Author]: WU Xin-yuan (1962 -), Male, Tongcheng Hubei, Deputy Chief Physician, M.B., Tel: 13971827695, E-mail: wuxinyuan2003@126.com

Received: 2011-11-28 Revised: 2012-01-05 JHMC, 2012; 18(6): 802-804

View from specialist: It is creative, and of certain scientific and educational value.

[ABSTRACT] Objective: To investigate the clinical effects of adefovir dipivoxil on different genotype of HBV. Methods: A total of 183 HBV patients who received adefovir dipivoxil treatment in our hospital from Sep. 2006 to Sep. 2009 were enrolled in this research. All the patients received adefovir dipivoxil 10 mg per day and last for 48 weeks. 1.5 mL venous blood was taken from all the patients for DNA extraction before treatment. PCR amplified HBV DNA and then classified the genotype according to the DNA length. Results: Ninety-eight patients were type B and 75 patients were type C, while 10 patients were type B plus C. At 12, 24, 36 and 48 weeks, serum ALT level, HBV DNA decreased more than 2log10 and completely inhibition of the three genotypes had no significant difference. Conclusion: Adefovir dipivoxil has the same clinical effect for different HBV genotypes.

[KEY WORDS] Adefovir Dipivoxil; Genotype; HBV